When stratified survival analyses were performed, patients with lymph node metastasis/advanced clinical stages and high Wnt3a expression had worse OS rates than patients with other features (P < 0.001). The gene discussed is WNT3A; the disease is metastatic malignant neoplasm in the lymph nodes.